Tag: cancer

DALLAS, 04 juill. 2025 (GLOBE NEWSWIRE) -- La Crosetto Foundation for the Reduction of Cancer Deaths, une organisation à but non lucratif agréée, lance un « appel urgent aux membres du Parlement européen et des parlements nationaux : il faut geler les financements destinés à la phase 2 des mises à niveau des expériences ATLAS et CMS du CERN ».

According to Towards FnB, the global vegan food market size is valued at USD 22.38 billion in 2025 to an impressive USD 55.88 billion by 2034, growing at a robust CAGR of 10.7% during the forecast period from 2025 to 2034. This significant growth is driven by rising consumer demand for plant-based alternatives, increasing health consciousness, and expanding vegan product offerings across mainstream retail and foodservice channels.

DALLAS, July 04, 2025 (GLOBE NEWSWIRE) -- Die Crosetto Foundation for the Reduction of Cancer Deaths, eine anerkannte gemeinnützige Organisation, richtet einen „dringenden Appell an die Mitglieder des Europäischen Parlaments und der nationalen Parlamente: Die Finanzierung der Phase-2-Upgrades der ATLAS- und CMS-Experimente des CERN ist auszusetzen“.

PRESS RELEASE

COMMUNIQUÉ DE PRESSE

Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.

ORION CORPORATION
PRESS RELEASE
4 JULY 2025 at 09.00 EEST          

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.